ANI Pharmaceuticals | ANIP - Cash And Equivalent


ANI Pharmaceuticals reported $262.61M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
ANI Pharmaceuticals USD 262.61M 44.81M Sep/2025
Assertio Holdings USD 38.5M 8.59M Sep/2025
Aurora Cannabis CAD 95.69M 44.47M Sep/2025
Canopy Growth CAD 298.06M 171.86M Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Knight Therapeutics CAD 77.82M 34.34M Jun/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Omeros USD 1.9M 2.36M Jun/2025
Perrigo USD 432.1M 22.1M Sep/2025
Sun Pharmaceuticals INR 113.32B 33.19B Mar/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025